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of prescriptions, hospitalizations, visits and diagnostic examina-
tions in FVG. Direct medical costs were quantiﬁed in the per-
spective of the RHS and are expressed in Euro 2005. RESULTS:
We enrolled 2122 patients with incident CHF (mean age 78 ±
11 y.o.), 55.3% were women. The average cost person/year was
€5896, 54; 80% attributable to hospitalisations, 13.7% to drugs,
6.3% to other medical costs. A total of 1320 (62.2%) patients
died during the follow-up period. Mortality was higher in male
(p < 0.0001) and older subjects (p < 0.0001). CONLUSIONS:
CHF imposes a huge economic burden on NHS and society
because of the large number of hospitalisation and the high rate
of mortality after the ﬁrst event. Future investigations will be
conducted to asses the relationships between comorbidity, costs,
drug therapy and survival.
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OBJECTIVE: SOJA is a structured approach to the selection of
drugs for formulary inclusion. The aim of this study was to use
a modiﬁed SOJA approach in the selection of ACEI products for
use within a health board in Northern Ireland. METHODS: The
modiﬁed SOJA approach involved three phases in sequence: an
evidence based pharmacotherapeutic evaluation of all available
ACEI drug entities, a separate safety / risk assessment analysis
of products containing agents which exceeded the pharma-
cotherapeutic threshold and ﬁnally a budgetary impact analysis.
A comprehensive literature review and expert panel judgment,
informed selection of criteria (and their relative weighting) for
the pharmacotherapeutic evaluation. The resultant criteria /
scoring system was circulated (in questionnaire format) to pre-
scribers and stakeholders for comment. Based on statistical
analysis of the latter survey results, the ﬁnal scoring system was
developed. Drug entities which exceeded the evidence threshold
score were entered into a tendering process with pharmaceutical
suppliers. Products submitted as a result of the tendering process
were sequentially entered into the second and third phases of the
modiﬁed SOJA process (safety / risk assessment; budgetary
impact analysis). RESULTS: Five drug entities (from the 11 cur-
rently available in the UK) exceeded the evidence threshold and
22 from 26 submitted product lines, containing these drug enti-
ties, satisﬁed the safety evaluation / risk assessment criteria.
Three product lines, each containing a different drug entity, were
selected for formulary inclusion as a result of the budgetary
impact analysis. The estimated annual cost savings for ACEIs as
a result of this selection (based on estimated annual usage in
Deﬁned Daily Doses) in this health board was 41%. CONCLU-
SION: The modiﬁed SOJA approach has a signiﬁcant contribu-
tion to make in containing ACEI costs while retaining the same
level of patient care.
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OBJECTIVE: Risk assessment is important in determining the
management of patients with suspected or conﬁrmed coronary
artery disease (CAD). However, evidence supporting the clinical
impact of contrast echocardiography (CE) in this sphere is not
well known. The objective was to review and summarise the clin-
ical data for licensed and investigational applications of CE in
CAD, using systematic review methodology. METHODS: Full
publications of clinical studies of selected contrast agents were
identiﬁed through searches of electronic literature databases and
application of predeﬁned inclusion criteria. Studies were cate-
gorised and key data were extracted and tabulated for analysis.
No statistical pooling of data was undertaken due to study het-
erogeneity. RESULTS: 2275 abstracts were screened. 61 studies
met inclusion criteria and were categorised as follows: effective-
ness in image enhancement (23 studies); accuracy in the diagno-
sis of CAD, using coronary angiography as the diagnostic gold
standard (23 studies); myocardial viability assessment (16
studies); prognostic accuracy (2 studies). Using second genera-
tion contrast agents, diagnostic images were obtained in 48–98%
(median = 74%) of patients with suboptimal un-enhanced
images and several studies reported improved intra- and inter-
operator reproducibility. Reported sensitivities and speciﬁcities
for CAD diagnosis ranged from 41–100% (median = 86%) and
44–100% (median = 81%). Two studies reported that informa-
tion gained from myocardial contrast echocardiography (MCE)
provided incremental diagnostic value to that from left ventric-
ular function (LVF) assessment alone. Reported sensitivities 
and speciﬁcities of myocardial viability assessment by MCE 
for predicting LVF recovery ranged from 50–96% (median =
74%) and 44–96% (median = 83%). CONCLUSIONS: The
body of evidence suggests that effective use of contrast agents in
echocardiography extends beyond the licensed use in patients
with suboptimal baseline images. MCE is effective in the assess-
ment of myocardial perfusion in the diagnosis of CAD and the
detection of myocardial viability. Interpretation is limited by the
size of studies, lack of long-term outcomes and potential refer-
ral bias.
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OBJECTIVES: The 2002 AHA/ACC guideline recommends
acute coronary syndrome patients who undergo percutaneous
coronary intervention (ASC-PCI) be given 300mg loading dose
(LD) of clopidogrel, but higher LD has emerged in practice. A
recent trial involving 255 patients found 600mg of clopidogrel
had better outcomes than 300mg (Patti et al, 2005). The current
study investigates whether patients treated with higher clopido-
grel LD experience better outcomes in the usual care setting.
METHODS: We followed 6,282 ACS-PCI patients in a national
hospital database with time-stamp information (1/2003–9/2004)
for 60 days upon discharge. Using the time-stamp, LD was mea-
sured as total dose within 24-hour window of peri-PCI proce-
dure, and myocardial infarction (MI) was captured from
post-procedure lab tests. Patients receiving >300mg are grouped
into high LD (HLD) (nH = 1465) and £300mg, the low LD
group (LLD) (nL = 4152). Primary endpoints (i.e., death, stroke,
repeat revascularization, and MI) plus bleeding and re-admission
were monitored. Logistic regression tested effects of LD on
events with controls for risk. RESULTS: LD ranged from 75mg
to 1275mg. The HLD group did not experience better outcome.
While 28.49% of LLD experienced an event, the rate was
44.23% for the HLD (p < 0.0001). MI rate was higher for HLD
